Analysts’ Viewpoint
The global mesenchymal stem cells (MSCs) market witnessed steady growth in the past few years. MSCs have gained popularity in regenerative medicine, immunotherapy, and drug discovery due to unique characteristics such as self-renewal, differentiation potential, and immunomodulatory properties. Rise in prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders is expected to drive market expansion in the next few years. Furthermore, rise in patient preference for regenerative medicine is propelling market progress.
Increase in investment in research & development activities is projected to offer lucrative opportunities to market players. Companies are focusing on developing new products and technologies to expand product offerings and gain a competitive edge in the market.
Mesenchymal stem cells (MSCs) are a type of adult stem cell that can be found in various tissues in the body, including bone marrow, adipose tissue, and umbilical cord tissue. These are multipotent, which means they have the ability to differentiate into several different types of cell, such as bone cells, cartilage cells, and fat cells.
In addition to their differentiation potential, MSCs possess immunomodulatory properties. These can regulate the immune system by inhibiting the proliferation of T cells and activating regulatory T cells. This makes them an attractive candidate for the treatment of various autoimmune diseases and transplant rejection.
MSCs also secrete various growth factors and cytokines that are essential for tissue repair and regeneration. These factors can promote angiogenesis, reduce inflammation, and stimulate the growth and differentiation of other cells.
MSCs have gained attention in the past few years due to their unique properties such as self-renewal and multipotency. These cells have been used in various fields, including regenerative medicine, immunotherapy, and drug discovery.
Regenerative medicine is a rapidly growing field that aims to restore or replace damaged or diseased tissues and organs in the body. The field is based on the principles of tissue engineering, stem cell biology, and transplantation biology. Regenerative medicine holds great promise for the treatment of various diseases and conditions, including cancer, heart disease, diabetes, and neurological disorders. Mesenchymal stem cells are a key component of several regenerative medicine therapies.
Rise in awareness about regenerative medicine and its potential benefits has led to increase in demand for MSCs. Patients are increasingly interested in regenerative medicine therapies due to the potential to provide long-lasting and curative treatments for various diseases and conditions. Furthermore, advancements in technology and scientific research have contributed to the growing interest in regenerative medicine. Development of new tools and techniques for tissue engineering, gene editing, and stem cell manipulation have led to the discovery of new applications for MSCs and other stem cells.
Increase in demand for MSCs has led to the development of new manufacturing processes and quality control standards to ensure the safety and efficacy of MSC-based therapies. This has also led to the creation of new jobs and business opportunities in the regenerative medicine industry.
Research & development (R&D) activities are critical for the advancement of any industry, and the mesenchymal stem cells (MSCs) market is no exception. Key players in the market are investing significantly in R&D activities to develop new products and technologies, which has led to the discovery of new applications for MSCs and improved manufacturing processes.
One of the primary goals of R&D activities in the MSCs market is to discover new applications for MSC-based therapies. MSCs have shown promise in the treatment of various diseases and conditions, including autoimmune disorders, cardiovascular diseases, and neurological disorders. By investing in R&D, companies are able to explore new applications for MSCs and develop innovative therapies that have the potential to improve patient outcomes.
R&D activities in the mesenchymal stem cells market are focused on improving manufacturing processes. This includes the development of new technologies for cell culture, expansion, and characterization, as well as the implementation of quality control standards to ensure the safety and efficacy of MSC-based therapies. Improved manufacturing processes have led to reduced costs and improved product quality, which has made MSC-based therapies more accessible to patients.
R&D activities in the market are also focused on improving the delivery of MSC-based therapies. This includes the development of new delivery methods, such as targeted delivery systems and gene-editing technologies, which can improve the efficacy and safety of MSC-based therapies. Investment in R&D activities in the MSCs market has also led to the creation of business opportunities.
In terms of products & services, the product segment dominated the global mesenchymal stem cells industry in 2022. The is ascribed to increase in demand for MSC-based products and availability of a range of products for various applications. MSC-based products are used in various fields, including regenerative medicine, drug discovery, and basic research. Demand for these products is expected to increase in the next few years. Development of new MSC-based products and technologies contributed to the growth of the product segment.
Based on type, the allogenic segment accounted for the largest global mesenchymal stem cells market share in 2022. The segment includes MSCs derived from a donor, rather than from the patient's own cells (autologous). Growth of the allogenic segment can be attributed to lower cost and faster production time compared to autologous MSCs. Allogenic MSCs can be mass-produced and stored for future use, making them more readily available for clinical use. Furthermore, allogenic MSCs can be used in patients who do not have viable autologous MSCs or who require repeated treatments.
Surge in demand for MSC-based products and therapies in various applications, such as regenerative medicine, drug discovery, and basic research, has also contributed to the growth of the allogenic segment. Key players in the MSCs market are investing in the development of new allogenic MSC-based products and therapies to meet the growing demand.
In terms of source of isolation, the cord blood segment dominated the global market in 2022. This is ascribed to non-invasive and painless collection procedure compared to other sources of MSCs such as bone marrow. Cord blood contains a higher concentration of MSCs than other sources, making it an attractive option for cell-based therapies. Furthermore, cord blood MSCs are less likely to cause immune rejection as these are less mature and have not been exposed to environmental stimuli that could lead to immune recognition.
Rise in demand for MSC-based products and therapies in various applications, such as regenerative medicine, drug discovery, and basic research, contributed to the growth of the cord blood segment. Key players in the mesenchymal stem cells market are investing in the development of new cord blood MSC-based products and therapies to meet the growing demand from customers.
Based on indication, the musculoskeletal diseases segment led the global mesenchymal stem cells market in 2022. MSCs have been shown to have therapeutic potential in the treatment of a range of musculoskeletal diseases, including osteoarthritis, osteoporosis, and rheumatoid arthritis. Growth of the segment can be attributed to high prevalence of musculoskeletal disorders globally, increase in the elderly population, and limitations of current treatments for these diseases. MSC-based therapies have shown promising results in preclinical and clinical trials for the treatment of musculoskeletal diseases, and their potential for regenerating damaged tissues and reducing inflammation has generated a lot of interest in the medical community.
Development of novel MSC-based products and technologies for the treatment of musculoskeletal diseases has also contributed to the growth of the musculoskeletal diseases segment. Key players in the mesenchymal stem cells market are investing in research & development activities to develop new and innovative MSC-based products and therapies for the treatment of musculoskeletal diseases.
As per mesenchymal stem cells market trends, North America accounted for the largest share of the global market in 2022. This is ascribed to presence of a large number of key players, favorable regulatory policies, and increase in investment in research & development activities.
North America is home to several leading biopharmaceutical companies that are actively involved in the development and commercialization of MSC-based products and therapies. These companies have a strong focus on innovation and are investing in research & development activities to develop new and improved MSC-based products and technologies. Furthermore, the region has a favorable regulatory environment for the development and commercialization of MSC-based products and therapies. Regulatory bodies such as the FDA in the U.S. have provided clear guidelines for the development and clinical evaluation of MSC-based products, which has helped to accelerate the approval process for these products.
The mesenchymal stem cells market in Asia Pacific is projected to grow at a rapid pace during the forecast period. The region has a large population base, rapidly growing economy, and increasing investment in healthcare infrastructure. China, Japan, South Korea, and India are the major markets for MSCs in the region. China is the largest market for MSCs, with a significant number of clinical trials and research studies being conducted. The Government of China has provided significant funding for the development of MSC-based products and therapies, which has helped to boost the growth of the MSCs market in the country.
Asia Pacific is also home to several key players, who are actively involved in the development and commercialization of MSC-based products and therapies. These companies are leveraging the region's large patient pool and favorable regulatory environment to expand their operations and increase their market share.
This report provides profiles of leading players operating in the global mesenchymal stem cells industry. These include Thermo Fisher Scientific, Inc., Cytiva (Danaher Corporation), FUJIFILM Irvine Scientific (FUJIFILM Corporation), Merck KGaA, Lonza Group Ltd., STEMCELL Technologies, Inc., Takara Bio, Inc., Sartorius AG, Miltenyi Biotec GmbH, and PromoCell GmbH. These players engage in merger & acquisition, strategic collaborations, and new product launches to expand presence and increase market share.
The report profiles top players based on various factors including a company overview, financial summary, strategies, product portfolio, segments, and recent advancements in the market.
|
Attribute |
Detail |
|
Size in 2022 |
US$ 3.2 Bn |
|
Forecast (Value) in 2031 |
More than US$ 10.1 Bn |
|
Growth Rate (CAGR) |
12.7% |
|
Forecast Period |
2023–2031 |
|
Historical Data Available for |
2017–2022 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global industry was valued at US$ 3.2 Bn in 2022.
It is projected to reach more than US$ 10.1 Bn by 2031.
The CAGR is anticipated to be 12.7% from 2023 to 2031.
The allogenic segment held the largest share of the market in 2022.
North America is expected to account for significant market share during the forecast period.
Thermo Fisher Scientific, Inc., Cytiva (Danaher Corporation), FUJIFILM Irvine Scientific (FUJIFILM Corporation), Merck KGaA, Lonza Group Ltd., STEMCELL Technologies, Inc., Takara Bio, Inc., Sartorius AG, Miltenyi Biotec GmbH, and PromoCell GmbH are the prominent players in the market.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Mesenchymal Stem Cells Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Mesenchymal Stem Cells Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. List Of Major Research Institutes Involved In Mesenchymal Stem Cells Studies
5.3. Mesenchymal Stem Cells: Current Trends and Future Prospects in a Variety of Disease Conditions
5.4. Regulatory Scenario by Region/globally
5.5. COVID-19 Pandemic Impact on Industry
6. Global Mesenchymal Stem Cells Market Analysis and Forecast, by Products & Services
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Products & Services, 2017–2031
6.3.1. Product
6.3.1.1. Workflow Type
6.3.1.2. Product Type
6.3.2. Services
6.4. Market Attractiveness Analysis, by Products & Services
7. Global Mesenchymal Stem Cells Market Analysis and Forecast, by Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Type, 2017–2031
7.3.1. Autologous
7.3.2. Allogenic
7.4. Market Attractiveness Analysis, by Type
8. Global Mesenchymal Stem Cells Market Analysis and Forecast, by Source of Isolation
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Source of Isolation, 2017–2031
8.3.1. Bone Marrow
8.3.1.1. Adipose
8.3.1.2. Cord Blood
8.3.1.3. Peripheral Blood
8.3.2. Dental Pulp
8.3.3. Others (lung tissue, umbilical cord tissue, etc.)
8.4. Market Attractiveness Analysis, by Source of Isolation
9. Global Mesenchymal Stem Cells Market Analysis and Forecast, by Indication
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Indication, 2017–2031
9.3.1. Musculoskeletal Diseases
9.3.2. Cardiovascular Diseases
9.3.3. Neuro Disorders
9.3.4. Autoimmune Diseases
9.3.5. Cancer
9.3.6. GvHD
9.3.7. Pulmonary Diseases
9.3.8. Others
9.4. Market Attractiveness Analysis, by Indication
10. Global Mesenchymal Stem Cells Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Mesenchymal Stem Cells Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Products & Services, 2017–2031
11.2.1. Product
11.2.1.1. Workflow Type
11.2.1.2. Product Type
11.2.2. Services
11.3. Market Value Forecast, by Type, 2017–2031
11.3.1. Autologous
11.3.2. Allogenic
11.4. Market Value Forecast, by Source of Isolation, 2017–2031
11.4.1. Bone Marrow
11.4.1.1. Adipose
11.4.1.2. Cord Blood
11.4.1.3. Peripheral Blood
11.4.2. Dental Pulp
11.4.3. Others (lung tissue, umbilical cord tissue, etc.)
11.5. Market Value Forecast, by Indication , 2017–2031
11.5.1. Musculoskeletal Diseases
11.5.2. Cardiovascular Diseases
11.5.3. Neuro Disorders
11.5.4. Autoimmune Diseases
11.5.5. Cancer
11.5.6. GvHD
11.5.7. Pulmonary Diseases
11.5.8. Others
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Product
11.7.2. By Type
11.7.3. By Source of Isolation
11.7.4. By Indication
11.7.5. By Country
12. Europe Mesenchymal Stem Cells Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Products & Services, 2017–2031
12.2.1. Product
12.2.1.1. Workflow Type
12.2.1.2. Product Type
12.2.2. Services
12.3. Market Value Forecast, by Type, 2017–2031
12.3.1. Autologous
12.3.2. Allogenic
12.4. Market Value Forecast, by Source of Isolation, 2017–2031
12.4.1. Bone Marrow
12.4.1.1. Adipose
12.4.1.2. Cord Blood
12.4.1.3. Peripheral Blood
12.4.2. Dental Pulp
12.4.3. Others (lung tissue, umbilical cord tissue, etc.)
12.5. Market Value Forecast, by Indication , 2017–2031
12.5.1. Musculoskeletal Diseases
12.5.2. Cardiovascular Diseases
12.5.3. Neuro Disorders
12.5.4. Autoimmune Diseases
12.5.5. Cancer
12.5.6. GvHD
12.5.7. Pulmonary Diseases
12.5.8. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Product
12.7.2. By Type
12.7.3. By Source of Isolation
12.7.4. By Indication
12.7.5. By Country/Sub-region
13. Asia Pacific Mesenchymal Stem Cells Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Products & Services, 2017–2031
13.2.1. Product
13.2.1.1. Workflow Type
13.2.1.2. Product Type
13.2.2. Services
13.3. Market Value Forecast, by Type, 2017–2031
13.3.1. Autologous
13.3.2. Allogenic
13.4. Market Value Forecast, by Source of Isolation, 2017–2031
13.4.1. Bone Marrow
13.4.1.1. Adipose
13.4.1.2. Cord Blood
13.4.1.3. Peripheral Blood
13.4.2. Dental Pulp
13.4.3. Others (lung tissue, umbilical cord tissue, etc.)
13.5. Market Value Forecast, by Indication , 2017–2031
13.5.1. Musculoskeletal Diseases
13.5.2. Cardiovascular Diseases
13.5.3. Neuro Disorders
13.5.4. Autoimmune Diseases
13.5.5. Cancer
13.5.6. GvHD
13.5.7. Pulmonary Diseases
13.5.8. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. South Korea
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Product
13.7.2. By Type
13.7.3. By Source of Isolation
13.7.4. By Indication
13.7.5. By Country/Sub-region
14. Latin America Mesenchymal Stem Cells Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Products & Services, 2017–2031
14.2.1. Product
14.2.1.1. Workflow Type
14.2.1.2. Product Type
14.2.2. Services
14.3. Market Value Forecast, by Type, 2017–2031
14.3.1. Autologous
14.3.2. Allogenic
14.4. Market Value Forecast, by Source of Isolation, 2017–2031
14.4.1. Bone Marrow
14.4.1.1. Adipose
14.4.1.2. Cord Blood
14.4.1.3. Peripheral Blood
14.4.2. Dental Pulp
14.4.3. Others (lung tissue, umbilical cord tissue, etc.)
14.5. Market Value Forecast, by Indication , 2017–2031
14.5.1. Musculoskeletal Diseases
14.5.2. Cardiovascular Diseases
14.5.3. Neuro Disorders
14.5.4. Autoimmune Diseases
14.5.5. Cancer
14.5.6. GvHD
14.5.7. Pulmonary Diseases
14.5.8. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Product
14.7.2. By Type
14.7.3. By Source of Isolation
14.7.4. By Indication
14.7.5. By Country/Sub-region
15. Middle East & Africa Mesenchymal Stem Cells Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Products & Services, 2017–2031
15.2.1. Product
15.2.1.1. Workflow Type
15.2.1.2. Product Type
15.2.2. Services
15.3. Market Value Forecast, by Type, 2017–2031
15.3.1. Autologous
15.3.2. Allogenic
15.4. Market Value Forecast, by Source of Isolation, 2017–2031
15.4.1. Bone Marrow
15.4.1.1. Adipose
15.4.1.2. Cord Blood
15.4.1.3. Peripheral Blood
15.4.2. Dental Pulp
15.4.3. Others (lung tissue, umbilical cord tissue, etc.)
15.5. Market Value Forecast, by Indication, 2017–2031
15.5.1. Musculoskeletal Diseases
15.5.2. Cardiovascular Diseases
15.5.3. Neuro Disorders
15.5.4. Autoimmune Diseases
15.5.5. Cancer
15.5.6. GvHD
15.5.7. Pulmonary Diseases
15.5.8. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Product
15.7.2. By Type
15.7.3. By Source of Isolation
15.7.4. By Indication
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company, 2021
16.3. Company Profiles
16.3.1. Thermo Fisher Scientific, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Cytiva (Danaher Corporation)
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. FUJIFILM Irvine Scientific (FUJIFILM Corporation)
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Merck KGaA
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Lonza Group Ltd.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. STEMCELL Technologies, Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Takara Bio, Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Sartorius AG
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Miltenyi Biotec GmbH
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. PromoCell GmbH
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
List of Tables
Table 01: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032
Table 02: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032
Table 03: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032
Table 04: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2032
Table 05: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032
Table 06: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Region, 2017–2032
Table 07: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Country, 2017–2032
Table 08: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032
Table 09: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032
Table 10: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032
Table 11: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2031
Table 12: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032
Table 13: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2032
Table 14: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032
Table 15: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032
Table 16: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032
Table 17: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2031
Table 18: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032
Table 19: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2032
Table 20: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032
Table 21: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032
Table 22: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032
Table 23: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2031
Table 24: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032
Table 25: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2032
Table 26: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032
Table 27: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032
Table 28: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032
Table 29: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2031
Table 30: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032
Table 31: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2032
Table 32: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Products & Services, 2017–2032
Table 33: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Product, 2017–2032
Table 34: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Type, 2017–2032
Table 35: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Source of Isolation, 2017‒2031
Table 36: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, by Indication, 2017–2032
List of Figures
Figure 01: Global Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, 2017–2032
Figure 02: Global Mesenchymal Stem Cells Market Value Share, by Products & Services, 2022
Figure 03: Global Mesenchymal Stem Cells Market Value Share, by Type, 2022
Figure 04: Global Mesenchymal Stem Cells Market Value Share, by Source of Isolation, 2022
Figure 05: Global Mesenchymal Stem Cells Market Value Share, by Indication, 2022
Figure 06: Global Mesenchymal Stem Cells Market Value Share Analysis, by Products & Services, 2022 and 2032
Figure 07: Global Mesenchymal Stem Cells Market Attractiveness Analysis, by Products & Services, 2023–2032
Figure 08: Global Mesenchymal Stem Cells Market Revenue (US$ Mn), by Product, 2017–2032
Figure 09: Global Mesenchymal Stem Cells Market Revenue (US$ Mn), by Services, 2017–2032
Figure 10: Global Mesenchymal Stem Cells Market Value Share Analysis, by Type, 2022 and 2032
Figure 11: Global Mesenchymal Stem Cells Market Attractiveness Analysis, by Type, 2023–2032
Figure 12: Global Mesenchymal Stem Cells Market Revenue (US$ Mn), by Autologous, 2017–2032
Figure 13: Global Mesenchymal Stem Cells Market Revenue (US$ Mn), by Allogenic, 2017–2032
Figure 14: Global Mesenchymal Stem Cells Market Value Share Analysis, by Source of Isolation, 2022 and 2032
Figure 15: Global Mesenchymal Stem Cells Market Attractiveness Analysis, by Source of Isolation 2023–2032
Figure 16: Global Mesenchymal Stem Cells Market Value Share Analysis, by Indication, 2022 and 2032
Figure 17: Global Mesenchymal Stem Cells Market Attractiveness Analysis, by Indication, 2023–2032
Figure 18: Global Mesenchymal Stem Cells Market Value Share Analysis, by Region, 2022 and 2032
Figure 19: Global Mesenchymal Stem Cells Market Attractiveness Analysis, by Region, 2023–2032
Figure 20: North America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, 2017–2032
Figure 21: North America Mesenchymal Stem Cells Market Value Share Analysis, by Country, 2022 and 2032
Figure 22: North America Mesenchymal Stem Cells Market Attractiveness Analysis, by Country, 2023–2032
Figure 23: North America Mesenchymal Stem Cells Market Value Share Analysis, by Products & Services, 2022 and 2032
Figure 24: North America Mesenchymal Stem Cells Market Attractiveness Analysis, by Products & Services, 2023–2032
Figure 25: North America Mesenchymal Stem Cells Market Value Share Analysis, by Type, 2022 and 2032
Figure 26: North America Mesenchymal Stem Cells Market Attractiveness Analysis, by Type, 2023–2032
Figure 27: North America Mesenchymal Stem Cells Market Value Share Analysis, by Source of Isolation, 2022 and 2032
Figure 28: North America Mesenchymal Stem Cells Market Attractiveness Analysis, by Source of Isolation 2023–2032
Figure 29: North America Mesenchymal Stem Cells Market Value Share Analysis, by Indication, 2022 and 2032
Figure 30: North America Mesenchymal Stem Cells Market Attractiveness Analysis, Indication, 2023–2032
Figure 31: Europe Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, 2017–2032
Figure 32: Europe Mesenchymal Stem Cells Market Value Share Analysis, by Country/Sub-region, 2022 and 2032
Figure 33: Europe Mesenchymal Stem Cells Market Attractiveness Analysis, by Country/Sub-region, 2023–2032
Figure 34: Europe Mesenchymal Stem Cells Market Value Share Analysis, by Products & Services, 2022 and 2032
Figure 35: Europe Mesenchymal Stem Cells Market Attractiveness Analysis, by Products & Services, 2023–2032
Figure 36: Europe Mesenchymal Stem Cells Market Value Share Analysis, by Type, 2022 and 2032
Figure 37: Europe Mesenchymal Stem Cells Market Attractiveness Analysis, by Type, 2023–2032
Figure 38: Europe Mesenchymal Stem Cells Market Value Share Analysis, by Source of Isolation, 2022 and 2032
Figure 39: Europe Mesenchymal Stem Cells Market Attractiveness Analysis, by Source of Isolation 2023–2032
Figure 40: Europe Mesenchymal Stem Cells Market Value Share Analysis, by Indication, 2022 and 2032
Figure 41: Europe Mesenchymal Stem Cells Market Attractiveness Analysis, Indication, 2023–2032
Figure 42: Asia Pacific Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, 2017–2032
Figure 43: Asia Pacific Mesenchymal Stem Cells Market Value Share Analysis, by Country/Sub-region, 2022 and 2032
Figure 44: Asia Pacific Mesenchymal Stem Cells Market Attractiveness Analysis, by Country/Sub-region, 2023–2032
Figure 45: Asia Pacific Mesenchymal Stem Cells Market Value Share Analysis, by Products & Services, 2022 and 2032
Figure 46: Asia Pacific Mesenchymal Stem Cells Market Attractiveness Analysis, by Products & Services, 2023–2032
Figure 47: Asia Pacific Mesenchymal Stem Cells Market Value Share Analysis, by Type, 2022 and 2032
Figure 48: Asia Pacific Mesenchymal Stem Cells Market Attractiveness Analysis, by Type, 2023–2032
Figure 49: Asia Pacific Mesenchymal Stem Cells Market Value Share Analysis, by Source of Isolation, 2022 and 2032
Figure 50: Asia Pacific Mesenchymal Stem Cells Market Attractiveness Analysis, by Source of Isolation 2023–2032
Figure 51: Asia Pacific Mesenchymal Stem Cells Market Value Share Analysis, by Indication, 2022 and 2032
Figure 52: Asia Pacific Mesenchymal Stem Cells Market Attractiveness Analysis, Indication, 2023–2032
Figure 53: Latin America Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, 2017–2032
Figure 54: Latin America Mesenchymal Stem Cells Market Value Share Analysis, by Country/Sub-region, 2022 and 2032
Figure 55: Latin America Mesenchymal Stem Cells Market Attractiveness Analysis, by Country/Sub-region, 2023–2032
Figure 56: Latin America Mesenchymal Stem Cells Market Value Share Analysis, by Products & Services, 2022 and 2032
Figure 57: Latin America Mesenchymal Stem Cells Market Attractiveness Analysis, by Products & Services, 2023–2032
Figure 58: Latin America Mesenchymal Stem Cells Market Value Share Analysis, by Type, 2022 and 2032
Figure 59: Latin America Mesenchymal Stem Cells Market Attractiveness Analysis, Type, 2023–2032
Figure 60: Latin America Mesenchymal Stem Cells Market Value Share Analysis, by Source of Isolation, 2022 and 2032
Figure 61: Latin America Mesenchymal Stem Cells Market Attractiveness Analysis, Source of Isolation, 2023–2032
Figure 62: Latin America Mesenchymal Stem Cells Market Value Share Analysis, by Indication, 2022 and 2032
Figure 63: Latin America Mesenchymal Stem Cells Market Attractiveness Analysis, Indication, 2023–2032
Figure 64: Middle East & Africa Mesenchymal Stem Cells Market Value (US$ Mn) Forecast, 2017–2032
Figure 65: Middle East & Africa Mesenchymal Stem Cells Market Value Share Analysis, by Country/Sub-region, 2022 and 2032
Figure 66: Middle East & Africa Mesenchymal Stem Cells Market Attractiveness Analysis, by Country/Sub-region, 2023–2032
Figure 67: Middle East & Africa Mesenchymal Stem Cells Market Value Share Analysis, by Products & Services, 2022 and 2032
Figure 68: Middle East & Africa Mesenchymal Stem Cells Market Attractiveness Analysis, by Products & Services, 2023–2032
Figure 69: Middle East & Africa Mesenchymal Stem Cells Market Value Share Analysis, by Type, 2022 and 2032
Figure 70: Middle East & Africa Mesenchymal Stem Cells Market Attractiveness Analysis, by Type, 2023–2032
Figure 71: Middle East & Africa Mesenchymal Stem Cells Market Value Share Analysis, by Source of Isolation, 2022 and 2032
Figure 72: Middle East & Africa Mesenchymal Stem Cells Market Attractiveness Analysis, by Source of Isolation, 2023–2032
Figure 73: Middle East & Africa Mesenchymal Stem Cells Market Value Share Analysis, by Indication, 2022 and 2032
Figure 74: Middle East & Africa Mesenchymal Stem Cells Market Attractiveness Analysis, by Indication, 2023–2032
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Mesenchymal Stem Cells Market
